Teva reports success in a celiac disease study, highlighting the therapy's potential as a 'pipeline-in-a-product.' Meanwhile, BioMarin and Ascendis have settled a patent dispute, which may impact their respective product developments.

A literature review highlights the emergence of celiac disease following autologous stem cell transplantation (ASCT) in multiple myeloma patients. This intersection presents a rare diagnostic challenge for clinicians managing post-transplant complications.

Recent research highlights pancytopenia as a potential initial presentation of celiac disease, expanding the understanding of its clinical manifestations. This discovery may lead to improved diagnostic approaches for patients presenting with blood count abnormalities.

A recent study highlights fibrillar-type dermatitis herpetiformis as a rare variant that is often misidentified and infrequently linked to celiac disease. The report details two cases, emphasizing the absence of epidermal transglutaminase deposition.

Argenx acquires Forte Biosciences for $2.2 billion, enhancing its immunology portfolio. The acquisition centers on Forte's investigational antibody therapy, FB102, which shows promise in treating vitiligo and celiac disease.